|
Sign In to gain access to subscriptions and/or personal tools.
|
A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus
The Canadian Hydroxychloroquine Study Group
E Tsakonas
L Joseph
Division of Clinical Epidemiology, Montreal General Hospital, McGill University
J M Esdaile
Mary Pack Arthritis Centre and Vancouver General Hospital, University of British Colombia
D Choquette
J-L Senécal
Notre-Dame Hospital, University of Montreal
A Cividino
Hamilton Civic Hospital, McMaster University
D Danoff
Montreal General Hospital, McGill University
C K Osterland
C Yeadon
Royal Victoria Hospital, McGill University
C D Smith
Ottawa General Hospital, University of Ottawa
The ability of antimalarials to moderate severe disease activity in systemic lupus erythematosus (SLE) is plausible but undemonstrated. We evaluated the long-term effectiveness of maintaining treatment with hydroxychloroquine sulphate (HCQ) to prevent major flares in quiescent SLE. Forty-seven patients with quiescent SLE who had been randomized to take HCQ (n = 25) or placebo (n = 22) as part of a 24-week withdrawal trial were evaluated for an additional 3 years. The primary outcome was time to a major flare of SLE which resulted in either the institution of or an increase in the current dosage of prednisone of 10 mg/day or more, or institution of therapy with immunosuppressive agents. Secondary outcomes included the specific subtype of these major flares (glomerulonephritis, vasculitis or other) and hospitalization for an exacerbation of SLE. An intent-to-treat analysis was conducted.
Over the 42 months of study, 11 of 22 (50%) patients randomized initially to placebo, and seven of 25 (28%) patients randomized to continue treatment experienced a major flare. The relative risk of major flare for those randomized to continue HCQ compared with controls was 0.43 (95% CI: 0.17, 1.12). The relative risks for subtypes of flares were 0.26 (95% CI: 0.03, 2.54) for nephritis, 0.51 (95% CI: 0.09, 3.08) for vasculitis and 0.65 (95% CI: 0.17, 2.41) for flares characterized by other symptoms. The relative risk of hospitalization for major flare for patients randomized to continue hydroxychloroquine was 0.58 (95% CI: 0.13, 2.60). While the results are not statistically significant, they are compatible with the clinical belief that HCQ has a long-term protective effect against major disease flares in SLE and suggest that on average, HCQ use reduces major flares by 57% (95% CI: 83% reduction to 12% increase).
Key Words: systemic lupus erythematosus • hydroxychloroquine • nephritis • vasculitis • major flare
Lupus, Vol. 7, No. 2,
80-85 (1998)
DOI: 10.1191/096120398678919778
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. A. Heyneman
Systemic Lupus Erythematosus: A Therapeutic Update
Journal of Pharmacy Practice,
February 1, 2009;
22(1):
29 - 52.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Y. Yuen and J. E. Pope
Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials
Rheumatology,
September 1, 2008;
47(9):
1367 - 1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-{beta}2-glycoprotein I complexes to phospholipid bilayers
Blood,
September 1, 2008;
112(5):
1687 - 1695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Siso, M Ramos-Casals, A Bove, P Brito-Zeron, N Soria, S Munoz, A Testi, J Plaza, J Sentis, and A Coca
Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival
Lupus,
April 1, 2008;
17(4):
281 - 288.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Ann Rheum Dis,
February 1, 2008;
67(2):
195 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S Alarcon, G. McGwin, A. M Bertoli, B. J Fessler, J. Calvo-Alen, H. M Bastian, L. M Vila, J. D Reveille, and for the LUMINA Study Group
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)
Ann Rheum Dis,
September 1, 2007;
66(9):
1168 - 1172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. James, X. Kim-Howard, B. Bruner, M. Jonsson, M. McClain, M. Arbuckle, C. Walker, G. Dennis, J. Merrill, and J. Harley
Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus
Lupus,
June 1, 2007;
16(6):
401 - 409.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J.C. Sachet, E.F. Borba, E. Bonfa, C.G.C. Vinagre, V.M. Silva, and R.C. Maranhao
Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients
Lupus,
April 1, 2007;
16(4):
273 - 278.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco
Mycophenolate mofetil and systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11_suppl):
44 - 54.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Fernandez, G McGwin Jr., A M Bertoli, J Calvo-Alen, L M Vila, J D Reveille, G S Alarcon, and for the LUMINA Study Group
Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL)
Lupus,
October 1, 2006;
15(10):
700 - 704.
[PDF]
|
|
|
|
|
|
|
N Kasitanon, D M Fine, M Haas, L S Magder, and M Petri
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis
Lupus,
June 1, 2006;
15(6):
366 - 370.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E F Borba, J R Turrini-Filho, K A. Kuruma, C Bertola, M E. Pedalini, M C Lorenzi, and E Bonfa
Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry
Lupus,
April 1, 2004;
13(4):
223 - 227.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E Toubi, A Kessel, I Rosner, M Rozenbaum, M Lorber, D Paran, E Sabo, and T D Golan
Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE
Lupus,
April 1, 2003;
12(4):
297 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Molad, A Gorshtein, A J Wysenbeek, D Guedj, R Majadla, A Weinberger, and M Amit-Vazina
Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{
Lupus,
June 1, 2002;
11(6):
356 - 361.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R A Levy, V S Vilela, M J Cataldo, R C Ramos, J L. Duarte, B R Tura, E M. Albuquerque, and N R Jesus
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study
Lupus,
June 1, 2001;
10(6):
401 - 404.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D D'Cruz
Antimalarial therapy: a panacea for mild lupus?
Lupus,
March 1, 2001;
10(3):
148 - 151.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Rojas-Serrano and M H Cardiel
Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study
Lupus,
October 1, 2000;
9(8):
601 - 606.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D S Hallegua and D J Wallace
How accelerated atherosclerosis in SLE has changed our management of the disorder
Lupus,
March 1, 2000;
9(3):
228 - 231.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Corzillius and S-C Bae
Methodological issues of corticosteroid use in SLE clinical trials
Lupus,
October 1, 1999;
8(8):
692 - 697.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Petri
Hydroxychloroquine: past, present, future
Lupus,
February 1, 1998;
7(2):
65 - 67.
[PDF]
|
|
|
|
|
